BFC
EIDX

Bedel Financial Consulting’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Bedel Financial Consulting’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-54
Closed -$3K – 964
2020
Q1 		$3K Buy
+54
New +$2.75K ﹤0.01% 654

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bedel Financial Consulting's EIDX Position: Q2 2020 in Review

Bedel Financial Consulting sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q2 2020, closing a stake of 54 shares — an estimated $3K sold.

Bedel Financial Consulting first reported a position in EIDX in Q1 2020 and held it in 1 quarter. The position peaked at $3K in Q1 2020. 92 funds tracked by Wall St. Rank hold EIDX as of Q2 2020.

  • Bedel Financial Consulting reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Bedel Financial Consulting sold 54 Eidos Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $3K.
  • Bedel Financial Consulting first reported a position in Eidos Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Bedel Financial Consulting's Eidos Therapeutics, Inc. Common Stock position peaked at $3K in Q1 2020.
  • 92 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Bedel Financial Consulting's 13F filing for Q2 2020, filed 14 Jul 2020.